


PHARMACEUTICAL 2019

## Syndax Pharmaceuticals Inc Rank 238 of 363





Syndax 🌮



PHARMACEUTICAL 2019



## Syndax Pharmaceuticals Inc Rank 238 of 363

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 30%, being 6.6% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	83,346
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,105
Liabilities, Non-Current	14,786
Other Assets	219
Other Compr. Net Income	118
Other Expenses	0
Other Liabilities	0
Other Net Income	1,915
Other Revenues	1,517
Property and Equipment	373
Research and Development	60,106
Selling, General and Administrative Expense	17,287

Output Variable	Value in 1000 USD
Assets	83,938
Liabilities	30,891
Expenses	77,393
Revenues	1,517
Stockholders Equity	53,047
Net Income	-73,961
Comprehensive Net Income	-73,902
Economic Capital Ratio	30%

